Clinical trials: Alcoholic Liver Disease
Non-Alcoholic Fatty Liver Disease
Pyramidal Versus Continuous Training Effects on Fatty Liver
exercise is very important maneuver in the control of elevated liver enzymes in complaint of fatty liver .. the exercise forma are many.. from these exercises, pyramidal training or continues aerobic one.
- Trial name
- NCT06803108
- Testing
- pyramidal activity program, aerobic activity program
- Where
- Egypt
- Volunteers
- 38 people
- Sponsor
- Cairo University
NASH, Fatty Liver
Effects of Online App Weight Loss Programs on Liver Health in Obese Adults
The primary objective of this trial is to assess the effects of online app weight loss programs on liver health in obese adults.
- Conditions
- NASH, Fatty Liver, NAFLD, Weight Loss
- Trial name
- NCT05015491
- Testing
- Noom Healthy Weight Program
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Non-alcoholic Fatty Liver Disease
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH.
- Trial name
- NCT03166735
- Testing
- BI 1467335
- Where
- 44 sites in United States, Belgium and 7 more
- Volunteers
- 114 people
- Sponsor
- Boehringer Ingelheim
NASH - Nonalcoholic Steatohepatitis
Effect of DMR in the Treatment of NASH
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes.
- Trial name
- DMR_NASH_001 (NCT03536650)
- Testing
- DMR
- Where
- Belgium
- Volunteers
- 14 people
- Sponsor
- Erasme University Hospital
Fatty Liver Disease
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).
- Trial name
- NCT06585982
- Testing
- Treatment, Control
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Diponegoro
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Nonalcoholic Fatty Liver Disease
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of a low free sugar diet on lipid profile, glycemic indices, liver enzymes, inflammatory factors and hepatic steatosis and fibrosis in patients with Nonalcoholic fatty liver disease, 50 patients who referred…
- Trial name
- NCT04369521
- Testing
- low free sugar diet
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied.
- Trial name
- CERADIAB (NCT03447964)
- Testing
- dosing of sphingolipids
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Alcoholic Liver Disease, Chronic Hepatitis C Virus Infection
sgp130 in Chronic Human Liver Disease
Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known.
- Trial name
- NCT00770198
- Where
- Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Hepatic Steatosis, Dietary Fructose Exposure
Dietary Fructose on Microbiota and Hepatosteatosis
The consumption of sugar-sweetened beverages (SSB) has increased steadily over the past decades, resulting in the dramatic increase of fructose intake as it is one of the main ingredients of artificial sweeteners.
- Trial name
- NCT04898621
- Testing
- 75g fructose solution, 150g fructose solution
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Diabetes Mellitus, Type 2, Overweight and Obesity
The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 Diabetes
The primary aim of this randomized cross-over intervention study is to investigate the effect of four weeks of intermittent carbohydrate restriction (alternating between two days of normal dietary intake and two days of…
- Conditions
- Diabetes Mellitus, Type 2, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- INTERCARB (NCT06144593)
- Testing
- Dietary macronutrient composition
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Hvidovre University Hospital
NAFLD
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
- Trial name
- NCT04634643
- Testing
- Usual diet and physical activity
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Yale University
Nonalcoholic Steatohepatitis
Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)
1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH) 2.
- Trial name
- NCT03375008
- Testing
- Imaging diagnostic and biopsy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Korea University Guro Hospital
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04906421
- Testing
- TVB-2640
- Where
- 117 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Sagimet Biosciences Inc.
Nonalcoholic Steatohepatitis
Dapagliflozin Efficacy and Action in NASH
This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.
- Trial name
- DEAN (NCT03723252)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children
Nonalcoholic fatty liver disease is a serious health condition in overweight children which can lead to heart disease. This project will examine the links between liver health and cardiovascular risk factors in overweight and…
- Trial name
- SMART (NCT02383485)
- Testing
- Exercise, After-school program
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Augusta University
Non-alcoholic Steatohepatitis
The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects
- Trial name
- NCT04829123
- Testing
- HEC88473 injection
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Metabolic Encephalopathy
Prognostic Significance of Fatty Liver Disease in Bariatric Patients
Prospective non-randomized intervention case control study on patients with a BMI > 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Encephalopathy, Obesity, Morbid, Non-alcoholic Steatohepatitis
- Trial name
- PROMETHEUS (NCT03535142)
- Testing
- Bariatric surgery
- Where
- Denmark
- Volunteers
- 1,200 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Non Alcoholic Steatohepatitis
Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)
The study will determine the feasibility of using Bioenteric intragastric balloon (BIB) in the treatment of patients with Non alcoholic Steatohepatitis (NASH).
- Trial name
- NCT01761370
- Testing
- AHA diet plus exercise with BIB placement
- Where
- Singapore
- Volunteers
- 21 people
- Sponsor
- National University Hospital, Singapore
Insulin Resistance, Prediabetic State
Dexamethasone/Pancreatic Clamp P&F
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp…
- Conditions
- Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
- Trial name
- NCT06126354
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.